Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Urine Test Identifies Risk of Necrotizing Enterocolitis

By LabMedica International staff writers
Posted on 30 Apr 2013
In premature babies, abnormal gut bacteria can be found days before the onset of the devastating intestinal disease known as necrotizing enterocolitis (NEC).

Examination of stool samples from preterm infants by molecular techniques and urinary metabolomic analysis has revealed differences between those at risk of NEC and those who will not develop the disease. More...


Scientists at Cincinnati Children's Hospital (OH, USA) collaborating with other institutes, studied between October 2009 and August 2010, a total of 35 preterm infants of less than 29 weeks gestational age and whose weight was less than 1,200 grams at birth, The primary analysis included 11 infants who developed NEC and 21 control infants. The infant microbiome was analyzed by postnatal periods, 4 to 9 days and 10 to 16 days.

Bacterial DNA was extracted from infant stool samples using one of two methods: phenol-chloroform or the QiaAmp DNA stool kit (Qiagen Sciences; Germantown, MD, USA). The 16S ribosomal ribonucleic acid ( rRNA) gene was amplified and sequenced using 454 FLX Titanium sequencing (454 Life Sciences, Branford, CT, USA). Urine samples were analyzed by nuclear magnetic resonance.

Babies who later went on to develop NEC had a lower diversity of gut bacteria 4 to 9 days after birth, with increased level of Firmicutes or Enterobacteriaceae, but lacked the Propionibacterium found in healthy babies. All of the babies with NEC also had unusual levels of specific bacteria. Babies whose NEC started early, between 7 to 12 days after birth had abnormally high levels of Firmicutes, while babies whose NEC started later, 19 to 31 days, had high levels of Enterobacteriaceae. No difference was found in the relative abundance of Propionibacterium between NEC and control samples collected from days 10 to 16 of life.

No urinary metabolites differed significantly among all NEC cases and controls. However, three metabolites, alanine, pyridoxine (4-pyridoxate) and histidine, significantly distinguished NEC-I and NEC-II from each other as well as one of the NEC sub-types from controls.

Alanine was significantly higher in NEC-I versus NEC-II and NEC-I versus the control samples though the metabolite did not differ between all NEC versus control samples.

Ardythe L. Morrow, PhD, the senior author of the study said, "Our data show that onset of NEC appears to be related to having abnormally high levels of specific bacteria in the gut during the first week or two of life. Our data also indicate that a simple urine test looking at levels of alanine and histidine, which appear altered by these bacteria, can be used early in life to identify babies at risk of NEC." The study was published on April 16, 2013, in the journal Microbiome.

Related Links:

Cincinnati Children's Hospital
Qiagen Sciences
454 Life Sciences



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.